CO5570111A1 - NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORM - Google Patents
NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORMInfo
- Publication number
- CO5570111A1 CO5570111A1 CO05034788A CO05034788A CO5570111A1 CO 5570111 A1 CO5570111 A1 CO 5570111A1 CO 05034788 A CO05034788 A CO 05034788A CO 05034788 A CO05034788 A CO 05034788A CO 5570111 A1 CO5570111 A1 CO 5570111A1
- Authority
- CO
- Colombia
- Prior art keywords
- autologous
- concentrate
- giving
- factors
- thrombin
- Prior art date
Links
Abstract
Caracterizado por ser un Procedimiento Autólogo de una sola Fase, con pequeños Volúmenes de Sangre. Caracterizado por obtenerse un Concentrado Autólogo de Factores de Crecimiento Tisular en Concentraciones Biológicamente Activas y Viables. Caracterizado por ser un Procedimiento Autólogo que obtiene altas concentraciones de Fibrinógeno, Trombina y Plaquetas. Caracterizado por ser un Procedimiento físico con un solo proceso de Centrifugación Estandarizado a 279,5 RCF por 10 minutos. Caracterizado por dar un Concentrado Autólogo Libre de Eritrocitos, Leucocitos y factores Pro inflamatorios. Caracterizado por dar un Concentrado Autólogo sin Riesgo Inmunogénico eliminando la posibilidad de Rechazo Inmunológico. Caracterizado por dar un Concentrado Autólogo sin Riesgo de Transmisión de Enfermedades Virales o Priónicas. Caracterizado por dar un Concentrado de Fibrina y factores de Crecimiento, que permite mantener la viabilidad de los Tejido aumentado la Vascularización y Oxigenación del mismo, descartando completamente el rechazo tisular en los injertos.Characterized by being a single phase autologous procedure, with small volumes of blood. Characterized by obtaining an Autologous Concentrate of Tissue Growth Factors in Biologically Active and Viable Concentrations. Characterized by being an Autologous Procedure that obtains high concentrations of Fibrinogen, Thrombin and Platelets. Characterized as a Physical Procedure with a single Standard Centrifugation process at 279.5 RCF for 10 minutes. Characterized by giving an Autologous Concentrate Free of Erythrocytes, Leukocytes and Pro inflammatory factors. Characterized by giving an Autologous Concentrate without Immunogenic Risk eliminating the possibility of Immune Rejection. Characterized by giving an Autologous Concentrate without Risk of Transmission of Viral or Prion Diseases. Characterized by giving a Fibrin Concentrate and Growth factors, which allows to maintain the viability of the tissue, increasing Vascularization and Oxygenation thereof, completely discarding tissue rejection in grafts.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CO05034788A CO5570111A1 (en) | 2005-04-13 | 2005-04-13 | NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORM |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CO05034788A CO5570111A1 (en) | 2005-04-13 | 2005-04-13 | NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORM |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5570111A1 true CO5570111A1 (en) | 2005-10-31 |
Family
ID=40974237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05034788A CO5570111A1 (en) | 2005-04-13 | 2005-04-13 | NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORM |
Country Status (1)
Country | Link |
---|---|
CO (1) | CO5570111A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011061561A2 (en) * | 2009-11-19 | 2011-05-26 | Elda Restrepo | Method of obtaining regenerative molecular matrices and regenerative molecular matrices thus obtained |
-
2005
- 2005-04-13 CO CO05034788A patent/CO5570111A1/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011061561A2 (en) * | 2009-11-19 | 2011-05-26 | Elda Restrepo | Method of obtaining regenerative molecular matrices and regenerative molecular matrices thus obtained |
WO2011061561A3 (en) * | 2009-11-19 | 2012-08-23 | Elda Restrepo | Method of obtaining regenerative molecular matrices and regenerative molecular matrices thus obtained |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ehrenfest et al. | Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF) | |
ES2832727T3 (en) | Extracellular vesicles derived from human platelet lysate for use in medicine | |
Altaie et al. | Use of platelet lysate for bone regeneration-are we ready for clinical translation? | |
Jager et al. | Bone marrow concentrate: a novel strategy for bone defect treatment | |
Schallmoser et al. | Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells | |
Araki et al. | Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: maximization of platelet concentration and removal of fibrinogen | |
Rubio-Azpeitia et al. | Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience | |
Jonsdottir-Buch et al. | Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells | |
ES2811085T7 (en) | Compositions, uses, and preparation of platelet lysates | |
Blumberg et al. | The platelet as an immune cell—CD40 ligand and transfusion immunomodulation | |
Chou et al. | Autologous platelet concentrates in maxillofacial regenerative therapy | |
Naskou et al. | Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells | |
PE20180817A1 (en) | ABSORBING ARTICLE THAT HAS A HIGH CONTENT OF MATERIALS OF BIOLOGICAL ORIGIN | |
PE20071327A1 (en) | JOINT CULTURE OF PLACENTARY STEM CELLS AND STEM CELLS FROM A SECOND SOURCE | |
Fernández-Medina et al. | Systematic comparison of the effect of four clinical-grade platelet rich hemoderivatives on osteoblast behaviour | |
ATE395074T1 (en) | AUTOLOGOUS THROMBIN | |
DK1856272T3 (en) | Use of manufactured product and process for producing collagen solution and method for collagen separation of animal tissue | |
MX2019002288A (en) | Cell suspension for use in the treatment of lower extremity peripheral artery disease. | |
ES2807897T3 (en) | Stem cell therapy based on adipose stem cells | |
EP4292585A3 (en) | Methods for isolating umbilical cord blood plasma products, tissue and cellular exosomes, and compositions and methods of use thereof | |
da Silva et al. | Platelet-rich plasma lyophilization enables growth factor preservation and functionality when compared with fresh platelet-rich plasma | |
Zhang et al. | Comparative study of different anticoagulants and coagulants in the evaluation of clinical application of platelet-rich plasma (PRP) standardization | |
JP7416786B2 (en) | Method for preparing platelet release material | |
Narvaez-Flores et al. | Cytotoxic and anti-inflammatory effects of chitosan and hemostatic gelatin in oral cell culture | |
GB2574333A (en) | Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused | ||
FG | Application granted |